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There is an urgent need for a human immunodeficiency virus (HIV) vaccine that induces robust mucosal immunity. CD8 cyto-
toxic T lymphocytes (CTLs) apply substantial antiviral pressure, but CTLs to individual epitopes select for immune escape vari-
ants in both HIV in humans and SIV in macaques. Inducing multiple simian immunodeficiency virus (SIV)-specific CTLs may
assist in controlling viremia. We vaccinated 10Mane-A1*08401 female pigtail macaques with recombinant influenza viruses
expressing threeMane-A1*08401-restricted SIV-specific CTL epitopes and subsequently challenged the animals, along with five
controls, intravaginally with SIVmac251. Seroconversion to the influenza virus vector resulted and small, but detectable, SIV-spe-
cific CTL responses were induced. There was a boost in CTL responses after challenge but no protection from high-level viremia
or CD4 depletion was observed. All three CTL epitopes underwent a coordinated pattern of immune escape during early SIV
infection. CTL escape was more rapid in the vaccinees than in the controls at the more dominant CTL epitopes. Although CTL
escape can incur a “fitness” cost to the virus, a putative compensatory mutation 20 amino acids upstream from an immunodomi-
nant Gag CTL epitope also evolved soon after the primary CTL escape mutation. We conclude that vaccines based only on CTL
epitopes will likely be undermined by rapid evolution of both CTL escape and compensatory mutations. More potent and possi-
bly broader immune responses may be required to protect pigtail macaques from SIV.
The human immunodeficiency virus type 1 (HIV-1) pandemiccontinues to be a global health problem. Despite significant
efforts, an effective vaccine has not yet been developed, and it is
still unclear what a successful vaccination approachwill comprise.
Attempts to induce broadly reactive neutralizing antibodies have
thus far been unsuccessful. Non-neutralizing antibodies appear to
have afforded only modest protection in the recent Thai RV144
trial (1). Cytotoxic T lymphocyte (CTL) responses have been
shown to assist in the control of HIV in humans and simian im-
munodeficiency virus (SIV) inmacaques (2–9). Induction of CTL
immunity by adenovirus vaccines was not protective in human
trials (10), and a median of only one epitope-specific CTL re-
sponse was induced by the regimen (11). A sieve analysis of break-
through HIV sequence in the STEP adenovirus vaccine trial did,
however, show some impact of the CTL responses in terms of
selection for escape mutations (12). In the absence of complete
control of viremia, selection of immune escape variants can re-
duce viral replication capacity (reduce “fitness”) and slow down
disease progression.Mutations outside theCTL epitope can, how-
ever, partially compensate for the fitness cost of CTL escape mu-
tations (13–17). The degree to which compensatory mutations
negate fitness cost imputed by CTL escape mutations in the vac-
cination setting is not clear.
Broader CTL responses may impart more substantial control
of viremia (18, 19), as suggested by the “heterozygous advantage”
seen in subjects with a wider complement of HLA alleles (20, 21).
Alternatively, eliciting CTL responses to a small number of critical
epitopes pertinent for SIV controlmay be amore important factor
for vaccine design (7).
We recently described an influenza vector SIV vaccine model
whereby SIV CTL epitopes were inserted into the neuraminidase
(NA) gene of mouse-adapted attenuated influenza viruses. Infec-
tion of pigtail macaques via the respiratory route induced SIV-
specific CTL responses, but in pilot studies the induction of only
one SIV-specific CTL response resulted in selection of immune
escape variants and was not protective against SIVmac251 challenge
(22). We expanded our vectors to include three SIV-specific CTL
epitopes, all of which boosted CTL responses in small studies on
SIV-infected animals. In the present study, we analyzed the im-
munogenicity, efficacy, and evolution of immune escape SIV vari-
ants after vaccinationwith recombinant influenza viruses express-
ing three SIV-specific CTL epitopes in pigtail macaques.
MATERIALS AND METHODS
Animals. Fifteen naive female and two naive male colony-bred pigtail
macaques (Macaca nemestrina) were studied, all expressing the common
major histocompatibility complex (MHC) class I allele Mane-A1*08401
(previously namedMane-A*10) as confirmed using high-throughput se-
quencing (23). Animals were anesthetized intramuscularly with ketamine
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(10 mg/kg) prior to any procedures. All studies were approved by the
University of Melbourne animal ethics committee.
Recombinant influenza virus-SIV constructs. Six separate recombi-
nant influenza A viruses used in the trial were generated using an eight-
plasmid reverse genetics system as previously outlined and studied in
macaques (22, 24–27). Briefly, the six DNA constructs encoded eight in-
fluenza virus segments, including a genetically manipulated neuramini-
dase (NA) segment containing one Mane-A*10-restricted CD8 T cell
epitope sequence; either KP9 (SIVGag164-172), KVA10 (SIVTat114-123), or
KSA10 (SIV Tat87-96). The CD8 T cell epitopes were inserted separately
into theNA stalks of twomouse-adapted strains of influenza A virus using
recombinant PCR techniques (25). These viruses share the same internal
gene segments but differ in their surface glycoprotein hemagglutinin
(HA) and NA genes—X31 (H3N2, A/HKx31) and PR8 (H1N1, A/Puerto
Rico/8/1939). That is, the constructs consisted of X31-KP9, X31-KVA10,
X31-KSA10, PR8-KP9, PR8-KVA10, and PR8-KSA10. The control influ-
enza viruses consisted of X31 and PR8 without the inserted CD8 T cell
epitopes. The stability of the inserted peptide epitopes within the ex-
panded virions was confirmed by sequencing prior to vaccination.
Infection of pigtail macaques with recombinant influenza virus-
SIV. All three separate recombinant influenza virus-SIV constructs (ei-
ther PR8 or X31) were administered to 10 vaccinated animals (Table 1). A
total of 108 PFU of influenza virus was administered via the respiratory
tract (intranasally [i.n.] and intratracheally) in phosphate-buffered saline
as previously described (22). Corresponding wild-type influenza virus
(108 PFU)was administered to “control” animals. All animals received the
influenza viruses via the respiratory tract with the exception of four ma-
caques (two vaccinees and two controls) that received the first two inoc-
ulations intravaginally (i.vag.), followed by two inoculations via the respi-
ratory tract (Table 1). Vaccinations were given i.vag. based on the results
from previous murine studies where i.vag. immunization with influenza
A virus provided protectivemucosal immunity against homosubtypic and
heterosubtypic virus challenge via the respiratory tract (28). As a result, we
hypothesized that i.vag. inoculation might result in sufficient infection to
initiate an immune response in macaques.
The timing of influenza virus-SIV vaccination was as follows: week 0,
X31 influenza virus-SIV; week 4, PR8 influenza virus-SIV; week 9, X31
influenza virus-SIV; andweek 17, PR8 influenza virus-SIV (Table 1). Cor-
responding wild-type influenza virus (108 PFU) was administered to five
“control” animals as follows: week 0, PR8 influenza virus; week 4, X31
influenza virus; week 9, X31 influenza virus; and week 17, PR8 influenza
virus. Infection with influenza virus wasmonitored by quantitating influ-
enza virus RNA levels in serials swabs of the upper respiratory tract post-
vaccination during infection (22). Briefly, swabs were analyzed using a
SuperScript III One-Step reverse transcription-PCR (RT-PCR) system
(Invitrogen) and primers and a probe targeting the matrix gene using the
ABI 7500 real-time PCR system (Applied Biosciences). Seroconversion to
influenza A virus in serial plasma samples was measured by a hemagglu-
tination inhibition (HI) assay as previously described (29). Briefly, 25 l
of influenza virus was incubated at room temperature with 2-fold dilu-
tions of sera treated with receptor-destroying enzyme (RDE) (Deka
Seiken, Tokyo, Japan) for 1 h. Turkey red blood cells (25 l [vol/vol])
were added, and hemagglutination was observed 30 min later. Titers are
expressed as the reciprocal of the highest dilution of plasma where hem-
agglutination was prevented.
SIV challenge of pigtail macaques. All female macaques (10 recom-
binant influenza virus-SIV-immunized animals and 5 influenza virus-
immunized animals) were challenged i.vag. at week 25 with a 104 50%
tissue culture infective dose (TCID50) of SIVmac251 (kindly provided byN.
Miller, National Institutes of Health). In addition, two naive male ma-
caques used solely for pyrosequencing studies were challenged intrarec-
tally (i.r.) with a 104 TCID50 dose of SIVmac251 (Table 1). SIV infectionwas
assessed by monitoring SIV plasma RNA levels as previously described
(22). Three animals that did not become infected after the initial SIV
challenge were rechallenged i.vag. 7 weeks later (at week 32) with a 10-
fold-higher concentration of virus (105 TCID50 of SIVmac251). Two vacci-
nated animals (B0443 and B0527) were euthanized at day 10 to study
tissue samples after SIVmac251 challenge, so the total number of vaccinated
animals studied immunologically was 8. Animals weremonitored at serial
time points for total peripheral CD4 T cell depletion as previously de-
scribed (30). 7high CD4 T cells in the blood were also examined since it
has previously been demonstrated that a reduction in7high CD4 T cells
in the blood during SIV infection in rhesus macaques correlates with the
loss of intestinal lamina propria CD4 T cells, potentially providing a
noninvasive method to measure disease progression (31).
CD8 CTL responses by tetramer analysis. SIV-specific CD8 T cell
responses were measured using fresh whole heparinized blood by tetramer
stainingofCD3CD8 lymphocytesusingfluorescentMane-A01*084 tetra-
meric protein folded around either the KVA10 (SIV Tat114-123), the KSA10
(SIV Tat87-96), or the KP9 (SIV Gag164-172) peptide epitope as previously
described (22, 32). Expression of memory markers was assessed using a
monoclonal antibody cocktail of anti-CD3-AF700 (clone SP34-2), anti-
CD4-PE Cy7 (clone L200), anti-CD8-APC-H7 (clone SK1), anti-CD28
PerCP Cy5.5 (clone L293), and anti-CD95 fluorescein isothiocyanate (clone
DX2). Expressionof themucosal homingmarker47 integrinon tetramer-
TABLE 1 Vaccine groups and regimens
Test group n Animal no.a
Influenza virus-SIV vaccination (route, strain, dose [PFU]) at:
SIVmac251 challenge
(dose [TCID50],
route) at wk 25fWk 0 Wk 4 Wk 9 Wk 17
Vaccinees
(n 10)
8 25377, 26359, B0527*,
B0517, B0526,
B0440, B0547,
B0443*
i.n., H3N2-SIV, 108 i.n., H1N1-SIV, 108 i.n., H3N2-SIV, 108 i.n., H1N1-SIV, 108 104, i.vag.
2 45418†, C0933 i.vag., H3N2-SIV, 108 i.vag., H1N1-SIV, 108 i.n., H3N2-SIV, 108 i.n., H1N1-SIV, 108 104, i.vag.
Controls
(n 7)
3 19351, 19530†, B0508, i.n.d, H3N2b, 108 i.n., H1N1c, 108 i.n., H3N2, 108 i.n., H1N1, 108 104, i.vag.
2 19341, C3754† i.vag.e, H3N2, 108 i.vag., H1N1, 108 i.n., H3N2, 108 i.n., H1N1, 108 104, i.vag.
2 C3751‡, 5873‡ 104, i.r.
a *, Macaques euthanized at day 10 after SIV challenge; †, 3 macaques not infected after the SIVmac251 challenge at week 25 were rechallenged with a 10-fold-higher dose of
SIVmac251 (10
5 TCID50) at week 32; ‡, male macaques infected with SIV mac251 at the same time used as controls for pyrosequencing studies.
b X31 (H3N2, A/HKx31).
c PR8 (H1N1, A/Puerto Rico/8/1939).
d Macaques immunized intranasally (i.n.).
e Macaques immunized intravaginally (i.vag.).
f Note that female macaques were challenged i.vag., and male macaques were challenged intrarectally (i.r.).
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positive cells was measured by counterstaining with rat anti-human integrin
7 APC (BD Pharmingen, catalog no. 551082, clone FIB504) (31).
Real-time PCR for CTL escape at KP9. To quantify the viral levels of
wild-type (WT) or escape mutant (EM) quasispecies at the KP9 epitope,
we used a strain-specific real-time PCR assay developed in the laboratory
(33, 34). This assay uses a forward primer specific for either the nucleotide
mutation encoding the dominant K165R KP9 escapemutant or wild-type
sequence. Briefly cDNA was made by reverse transcribing RNA extracted
from EDTA-anticoagulated plasma and amplified by quantitative RT-
PCR using both WT and EM primers specific for KP9 on an Eppendorf
Realplex cycler. Analysis was performed using the Eppendorf Realplex
software, where baselines were set two cycles earlier than real reported
fluorescence.
Pyrosequencing for escape at KP9, KVA10, and KSA10. To examine
the kinetics of CD8 T cell selection, we isolated and pyrosequenced
plasma virus from 15 female animals in the vaccine trial and two addi-
tionalmale unvaccinated control animals at 10 serial time points fromday
10 toweek 20 after SIV infection as previously described (13). Briefly, viral
RNA from EDTA anticoagulated plasma was extracted using the QIAamp
MinElute virus spin kit or QIAamp Ultrasens RNA kit (Qiagen, Valencia,
CA). Viral RNA was reverse transcribed and amplified using the Super-
Script III One-Step RT-PCR system with Platinum TaqDNA Polymerase
High Fidelity (Invitrogen, Carlsbad, CA) and MID-tagged primers (cata-
log no. 454; Sigma Aldrich) spanning Gag164-172 (KP9; KKFGAEVVP)
and Tat114-123 (KVA10; KKETVEKAVA) and Tat87-96 (KSA10; KKAKAN
TSSA). The RT-PCR conditions were as follows: 50°C for 15min; 94°C for
2min; 40 cycles of 94°C for 15 s, 58°C for 30 s, and 68°C for 50 s; and then
68°C for 5 min. DNA from PCR products was purified by cutting out
appropriate bands froma1%agarose gel andusing aQiagen gel extraction
kit. Amplicons were pooled at equimolar ratios and sequenced by the
Australian Genome Research Facility using a Roche/454 system. Amino
acid variation within the three epitopes (Gag KP9, Tat KVA10, and Tat
KSA10)was examined using a customdata analysis pipeline inGalaxy, the
open source system for processing next-generation sequence data as de-
scribed previously (18, 35–37). Sequence reads were translated and
aligned into six reading frames and compared to a reference SIV sequence
using BLAT (BLAST-Like Alignment Tool) (18, 38). Reads with low-
quality bases within epitopes were discarded.
Calculation of escape rates.We calculated the escape rate E between
two time points ti and ti 1 (see the bold line segments in Fig. 7A) assum-
ing exponential growth/decay of viral strains during this time interval
(39):
E
1
ti1 ti
ln fEM(ti1)fEM(ti) fWT(ti)fWT(ti1),
where fEM and fWT are the fractions of EM andWT in the total viral load.
The time at whichWT drops to 50% (t50%) was estimated using linear
interpolation of fractions. For polymorphic escape, we defined the escape
mutant as comprising all sequences different from the WT at the consid-
ered epitope (fEM 1 fWT). In this case, t50% lies at the intersection of
fWT and fEM lines (see Fig. 7A).
RESULTS
Influenza virus-SIV inoculation of macaques. Inducing broader
CTL responses is an important goal of CTL-based HIV vaccines.
We developed six separate influenza viruses expressing three SIV
CTL epitopes that have previously been shown to induce SIV-
specific CD8 T cells responses in SIV-infected pigtail macaques
when administered via the respiratory tract (22) and evaluated
these vaccines in naive macaques. To assess the infectivity and
immunogenicity of recombinant influenza viruses expressing
three SIV Tat KVA10, Tat KSA10, and Gag KP9 epitopes, we im-
munized 10 Mane-A*10 pigtail macaques over a period of 119
days. Influenza inoculation used two alternating doses of both
H3N2 (X31) and H1N1 (PR8) strains (four vaccinations in total).
Five macaques in the control group were inoculated with wild-
type influenza virus strains at 108 PFU (n  5; Table 1). The
vaccine groupwas given amixture of three recombinant influenza
viruses (108 PFU of each) containing either KP9, KVA10 and
KSA10 inserted into the neuraminidase stalk of H1N1 (PR8) and
H3N2 (X31) (n 10; Table 1) as previously described (22, 40).
All animals received the influenza viruses via the respiratory
tract with the exception of four macaques (two vaccinees and two
controls) that received the first two inoculations i.vag. (Table 1)
since we hypothesized that i.vag. inoculation might result in suf-
ficient infection to initiate an immune response based on previous
murine studies (28). To evaluate humoral recognition of influ-
enza virus using the different routes of delivery of the influenza
virus-SIV construct, we measured serum hemagglutination inhi-
bition (HI) titers to both homologous parent viruses (H1N1 and
H3N2) (Fig. 1). HI titers to PR8 (H1N1) and X31 (H3N2) for
macaques given two i.vag. immunizations followed by two respi-
ratory immunizations in the control group and the vaccinee group
compared to those for controls and vaccinees given all immuni-
zations via the respiratory tract are shown in Fig. 1. Influenza virus
infection occurred in all macaques after two respiratory inocula-
tions (Fig. 1B andD). ThemeanHI titers were significantly higher
in both controls and vaccinees given two doses of influenza virus
via the respiratory tract compared to intravaginally (controls:
PR8, P 0.02; X31, P 0.03; vaccinees: PR8, P 0.05; X31, P
0.02 [Mann-Whitney]; Fig. 1). As a result, the four animals previ-
ously immunized via the vaginal tract received their third and
fourth inoculations via the respiratory tract. Thesemacaques sub-
sequently seroconverted to influenza virus, with HI titers similar
to macaques that had received all viruses via the respiratory tract
(Fig. 1). Influenza virus RNA could be recovered from nose or
larynx swabs 2 days after the first and second inoculations inmost
animals immunized by the respiratory route but was recovered
less often in animals inoculated i.vag. (Fig. 1E).
T cell immunogenicity after vaccination and SIV challenge.
To assess the immunogenicity of the recombinant influenza-SIV
vaccinations, we analyzed serial fresh blood samples for the pres-
ence of KVA10-, KSA10-, and KP9-specific CD8 T cells using spe-
cific tetramers. Modest, but significant KVA10 and KSA10 CD8 T
cell responses in vaccinees compared to controls were observed 2
weeks after the first immunization and 1 week after the final vac-
cination at week 18 (Fig. 2A; *, P  0.05). CTL responses to
KVA10 and KSA10 in all vaccinees were above the threshold of
detection (mean  3 the standard deviation of the individual
tetramer responses of all animals prior to vaccination) on at least
three separate occasions postvaccination (Fig. 2B). In contrast,
only one CTL response to KVA10 at one time point in the control
group was above this threshold of detection.
In contrast, the frequency of KP9-specific CD8T cell responses
in vaccinees postvaccination above the threshold of detection was
lower (only 7 of 10 vaccinees had responses above the threshold).
The magnitude of KP9-specific T cells responses postvaccination
were also lower; however, these responses were of similar magni-
tude to those measured in a previous trial, where two macaques
were also inoculated via the respiratory tract with the influenza
virus-KP9 vaccine (22).
To address whether SIV-specific immune responses were
primed by vaccination, we analyzed tetramer-specific CD8 T cell
responses following SIVmac251 challenge. All female macaques
Reece et al.
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were challenged intravaginally (i.vag.) and the twomalemacaques
with challenged intrarectally (i.r.) with a 104 TCID50 of SIVmac251
8 weeks after the final vaccination (or 105 TCID50 of SIVmac251 if
they did not become infected after the initial challenge). An anal-
ysis of the SIV-specific CD8 T cell responses after SIVmac251 chal-
lenge using tetramers showed that KVA10 and KP9 CD8 T cell
responses in vaccinees were both earlier and significantly higher at
3 weeks postchallenge compared to the controls (Fig. 2A, KVA10,
P  0.011; KP9, P  0.045 [Mann-Whitney test]), despite mini-
mal KP9 CD8 T cell responses after vaccination (Fig. 2B). It
FIG 1 Vaccination of pigtail macaques with recombinant influenza virus-SIV. A comparison between routes of delivery of influenza virus (controls) and
recombinant influenza virus-SIV vaccine (vaccinees) given intravaginally or via the respiratory tract. Hemagglutination inhibition (HI) titers in serial plasma
samples to PR8 (H1N1, shown as solid lines) andX31 (H3N2, shown as dashed lines) are illustrated. Lines represent individual animals; HA titers to PR8 andX31
for the same animal are shown with the same symbol, and individual animals are identified by specific symbols as shown in the legend. HI titers of controls
administered influenza virus via the vaginal tract and respiratory tract (A) and the respiratory tract only (B) are shown. HI titers of vaccinees administered
recombinant influenza virus-SIV vaccine via the vaginal tract and respiratory tract (C) and the respiratory tract only are also shown (D). (E) Recovery of influenza
virus RNA from nose, larynx, and vaginal swabs from vaccinees administered influenza virus-SIV via the respiratory tract (black), controls administered
influenza virus via the respiratory tract (gray), and vaccinees and controls administered via the vaginal tract (white). RNAwas recovered by PCR at day 0 and day
2 after the first and second influenza virus and influenza virus-SIV vaccinations.
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should also be noted that peripheral KSA10-specific CD8 T cell
responses were first detected at 5 weeks postchallenge, which is
considerably later than for the KP9- and KVA10-specific CD8 T
cell responses that were first observed at 2 weeks postchallenge.
Induction of7 integrin-expressing SIV-specificCD8T cells
after influenza virus-SIV vaccination and SIV challenge. Studies
in vitro have demonstrated that cells expressing high levels of
47 (47high) can bind toHIV and SIVsmmwith high affinity,
suggesting that these cells could be early targets for viral infection
in vivo (41). The role of 47 has also been demonstrated in the
mucosal homing of CD8 T cells in macaque models of SIV and
other viral infections (42, 43), and it has been found that gp120
binds to and signals via an activated form of 47 on CD4 T
lymphocytes (41). In addition, intravenous administration of a
recombinant rhesus monoclonal antibody against the 47 into
rhesus macaques just prior to and during acute SIV infection re-
sulted in a significant decrease in the plasma and gastrointestinal
tissue viral load compared to control SIV-infected rhesus ma-
caques (44). To assess the potential for the influenza virus-SIV
inoculations to inducemucosal homingCD8T cells, we examined
SIVKVA10-, KSA10-, andKP9-specific CD8T cells for high levels
of 7 expression (7high). Although the frequency of vaccine-in-
duced tetramer-specific CD8 T cells was low, the proportion of
high 7 KVA10-, KSA10-, and KP9-specific CD8 T cells was
greater after the fourth influenza virus-SIV boost (week 18) com-
pared to 1 week after the first influenza virus-SIV boost (data not
shown). This suggests that the mucosal vaccination may have in-
duced SIV-specific CD8 T cells with mucosal homing capabilities.
Since macaques were immunized with the influenza virus-SIV
vaccine via the respiratory tract, we examined mucosal homing
characteristics of SIV-specific CD8T cells after SIV challenge (Fig.
3). A progressive decline in the proportion of peripheral 7high
SIV KVA10-, KSA10-, and KP9-specific CD8 T cells was observed
out to week 15 after SIV challenge. Note that the percentage of
7high tetramer-positive cells could only be measured once te-
tramer-specific CTLs appeared in the periphery, explaining the
absences in time point values in the figures. For instance, periph-
eral KSA10-specific cells were not measured in the majority of
animals until week 5, whereas KP9-specific and KVA10-specific
CTL responses weremeasured at week 2. Flow cytometry dot plots
from a representative vaccinated macaque showing the decline in
CD957high CD8 SIV tetramer-positive cells after the emergence
of SIV tetramerpositive cells in theperiphery compared to atweek15
are shown in Fig. 3A. This decline is also evidentwhen examining the
proportions of 7high CD95 CD8 SIV tetramer-positive cells in
individual animals at serial timepoints after SIVmac251 challenge (Fig.
3B). The decrease in the proportion of 7high CD95CD8 SIV
tetramer-positive cells shortly after challenge compared to
during chronic infection was statistically significant (mean 	
the standard error [SE] of controls [KVA10, P  0.01; KSA10,
P  0.05; KP9, P  0.002] and vaccinees [KVA10, P  0.006;
KSA10, P  0.001; KP9, P  0.01] calculated using the Wil-
coxon test, Fig. 3C). The decline in 7high tetramer-positive
cells in the periphery was observed in both controls and vac-
cinees and may be explained by their migration to SIV-infected
mucosal tissues after SIV infection or death of this particular
subset of cells.
Outcome of SIV challenge. Eight weeks after the final vaccina-
tion, all 15 vaccinated female macaques were challenged i.vag.
with a 104 TCID50 of SIVmac251. Two additional male macaques,
added to the study to be used as controls for the pyrosequencing
studies, were challenged i.r. with a 104 TCID50 dose of SIVmac251
(Table 1). Fourteen of the seventeen animals became infected after
this initial challenge with SIVmac251; however, three macaques
(one vaccinee and two controls) did not become infected. As a
consequence, these three macaques were rechallenged with a 10-
fold-higher dose of SIVmac251 (10
5 TCID50) at week 32, after which
they became infected. There was no significant difference inmean
viral loads (Fig. 4A) or survival (Fig. 4B) between influenza virus-
SIV-vaccinated animals and influenza virus-vaccinated animals.
The mean (	SE) peak viral loads 2 weeks after challenge between
vaccinated and control groupswere almost identical: 7.70 (	0.54)
versus 7.73 (	0.71) log10 copies/ml, respectively. Although there
was a subtle difference in the viral loads between controls and vaccin-
ees during chronic infection, with the viral loads in the vaccinees
being slightly lower than the controls (Fig. 4A), thedifferencewasnot
found to be statistically significant when we compared the average
chronic viral loads from week 5 and week 20 between controls and
vaccinees using theMann-Whitney test (P 0.15).
Loss of CD4 T cells and 7high CD4 T cells postchallenge.
A decrease in total peripheral CD4 T cells postchallenge was ob-
served in both vaccinee and control groups, with no significant
difference between the groups (Fig. 4C). It has previously been
reported that memory CD4 T cells in peripheral blood express-
ing high levels of the47 receptor are preferentially infected and
depleted during acute SIV infection, and this depletion correlated
with depletion of gut CD4 T cells in rhesus macaques (31). We
thereforemeasured7high CD4T cells in serial blood samples, and
flow cytometry dot plots of CD95 7high CD4 T cells of a rep-
resentative vaccinated animal are shown in Fig. 5A. A decrease in
the proportion of CD95 7high CD4 T cells in most animals was
observed at week 2 to 3 during acute infection (31, 45) when
examining individual macaques before and after challenge with
SIVmac251 (Fig. 5B). Surprisingly, however, this decline was only
transient, and by week 10 after SIV challenge, the proportions of
peripheral CD957high CD4T cells had returned to prechallenge
levels. It is also interesting that the proportions of CD95 7high
CD4 T cells in blood in all macaques, with the exception of one,
increased at day 10 after SIV challenge prior to this decrease
(Fig. 5B). There was no significant difference in the proportion of
FIG 2 Detection of SIVGag (KP9) and Tat (KVA10 and KSA10) specific CD8 T cells in peripheral blood. Pigtail macaques were given four vaccinations at weeks
0, 4, 9, and 17with recombinant influenza virus-SIV (vaccinees) or influenza virus (controls) and challenged intravaginally at week 25with pathogenic SIVmac251.
(A) Themeans (	SE) of the proportion of CD8 T cells stained for KVA10/ManeA1*08401, KSA10/ManeA1*08401, and KP9/ManeA1*08401 tetramers at weeks
2 and 18 postvaccination and weeks 3 and 5 post SIVmac251 challenge weremeasured by using flow cytometry. Proportions of SIV-tetramer positive CD8
T cells
in vaccinees significantly higher than controls as determined by theMann-Whitney test (P 0.05) are highlighted with an asterisk (*). (B and C) Proportions of
CD8 T cells stained for KVA10/ManeA1*08401, KSA10/ManeA1*08401, and KP9/ManeA1*08401 tetramers for individual macaques in vaccinees (open
symbols, solid lines) and controls (solid symbols, dashed lines) after vaccination (B) and after SIVmac251 challenge (C). The horizontal line indicates the threshold
of detection (mean  3 the standard deviation of the individual tetramer responses of all animals prior to vaccination). Symbols for individual animals are
shown in Fig. 1.
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CD95 7high CD4 T cells in blood between the vaccinees and
controls (Fig. 5C).
An increase, followed by a transient decline and then a return
to baseline, of peripheral CD957high CD4T cellsmay represent
a redistribution of cells between the periphery and the mucosa.
That is, CD957high CD4 T cells migrate from themucosa to the
periphery during acute infection, leading to an increase in CD95
7high CD4 T cells in the periphery. Shortly after, CD95 7high
FIG 3 Expression of 7 integrin on SIV/Mane-A1*08401 tetramer-positive CD8 T cells. The expression of peripheral CD95 7high cells on CD3 CD8 SIV
tetramer-positive cells after challengewith SIVmac251 was determined using flow cytometry. (A) Flow cytometry dot plots froma representative vaccineemacaque
showing the proportion of CD95 7high cells when CD3 CD8 tetramer-positive cells first appear in the periphery: at week 2 postchallenge for KVA10- and
KP9-positive CD8 T cells and at week 5 for KSA10-positive CD8 T cells and during chronic infection at 15 weeks after SIV challenge. (B) Individual vaccinees
(open symbols, solid lines) and controls (solids symbols, dashed lines)macaques showing the proportion of CD95CD3CD8 SIV tetramer-positive cells with
7high expression at serial time points after SIV mac251 challenge. Symbols for individual animals are as defined in Fig. 1. (C) Means	 the SE of the proportions
of CD95 7high cells on CD3 CD8 SIV tetramer-positive cells on vaccinees () and controls () at week 2 after SIV challenge for KVA10 and KP9, at week
5 after SIV challenge for KSA10, and at week 15 after SIV challenge.
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CD4 T cells are either killed or migrate back to the periphery and
return to baseline levels as a result of an equilibration forming
between redistribution and loss of cells between the mucosa and
the periphery. Although these results are not consistent with the
loss of 7high CD4 T cells observed after challenge with SIV in
rhesusmacaques (31), the physiological significance of 47 dur-
ing SIV infection in pigtail macaques may be minimal.
Evolution of immune escape of SIV-specific CD8 T cells in-
duced by influenza virus-SIV vaccines. A possible explanation
for the lack of control of SIV viremia despite the priming of mul-
tiple CTL responses was the rapid evolution of immune escape.
We initially quantified CTL escape at the KP9 Gag epitope in
plasma viral RNA at serial time points from day 10 to week 20
using a strain-specific PCR assay (33, 34) and found that vaccina-
tion with recombinant influenza virus-SIV generally resulted in
an earlier generation of immune escape variants at the Gag KP9
CD8 T cell epitope compared to the control animals inoculated
with influenza virus alone. The findings for KP9 escape in two
representative vaccinees and controls are presented in Fig. 6A.
Although the Gag KP9CTL epitope usually escapes in amono-
morphic way (K165R at position 2), the two previously observed
Tat epitopes (KSA10, KVA10) escape in polymorphic ways (46)
across animals, so a strain-specific real-time PCR assay is not suit-
able for these epitopes. As a result, to assess escape at the KSA10
and KVA10 epitopes, we performed pyrosequencing across these
epitopes, as well as the KP9 epitope.
Analysis of immune escape from plasma RNA at the Gag KP9
epitope using pyrosequencing showed that immune escape not
only occurred earlier in vaccinees, often occurring 14 days after
inoculation, but also occurred very rapidly (i.e., at a high rate).
The same two representative vaccinees and controls showing es-
cape at KP9 by pyrosequencing are illustrated in Fig. 6B. Pyrose-
quencing was able to confirm results obtained using the KP9-
specific PCR assay, as illustrated in Fig. 6A (33, 34). In addition,
pyrosequencing revealed early and very rapid escape at the Tat
KVA10 andKSA10 epitopes (Fig. 6C andD). Asmentioned above,
this escape was polymorphic in nature. The divergent nature of
escape at the two Tat epitopes in control and vaccinee animals is
represented in Fig. 6C and D.
Since we obtained an average of 500 reads for each sequencing
time point using pyrosequencing, we could confidently detect the
emergence of a range of viral variants with escape mutations with
frequencies as low as 1% of circulating virus, which is consistent
with the recently published pyrosequencing error rate (18).
The rate of CTL escape provides an estimate of the pressure
applied by theCTL response (39, 47).We calculated bothmaximal
escape rate assuming exponential growth/decay of WT and EM
strains during this time interval (shown as bold lines in Fig. 7A)
(39) and the time for the EM to reach 50% of the total variants
(indicated as “t50%” in Fig. 7A). For polymorphic escape, we
defined the escape mutant as comprising all sequences different
fromWT at the considered epitope. The analysis of the time taken
for the virus to escape from 100 to 50% wild-type (WT) at the
three CTL epitopes revealed that KP9 and KVA10 escape in the
vaccinees emerged significantly earlier than in the control group.
That is, 50% WT virus at the KP9 and KVA10 epitope occurred
significantly earlier in vaccinees compared to controls (Mann-
Whitney test; KP9, 50 	 11 days versus 38 	 12 days, P  0.02;
KVA10, 31	 6 days versus 21	 1 days, P 0.037; Fig. 7B and C)
but did not occur significantly faster for KSA10 (90 	 14 days
versus 68 	 5 days, P  0.73) (Fig. 7D). In addition to escape
occurring earlier, the rate of escape was shown to be also signifi-
cantly quicker only for KVA10 (Mann-Whitney test; P 0.0041)
(Fig. 7C). The rapid emergence of KP9 and KVA10 escape mu-
tantsmay explain the failure to observe significantly lower viremia
FIG 4 Outcome of SIVmac251 challenge of macaques vaccinated with influenza-
SIV. Each macaque was challenged intravaginally with 104 TCID50 SIVmac251 at
week 25 (8 weeks after the final immunization). Three macaques (one vaccinee
and two controls) that did not become infected were rechallenged intravaginally
with a 10-fold-higher dose of SIVmac251 (10
5 TCID50) at week 32, after which they
came infected. Blood samples fromvaccinees () and controls ()were analyzed
for SIV RNA by RT-PCR. (A) Mean (	 the SE) of viral loads. (B) Kaplan-Meier
survival graph for SIV-infected pigtail macaques. (C) CD4 T cell loss for each
vaccine group. The mean values (	 the SE) of the percentage of CD4 T cells at
baseline are given. There were no significant differences between vaccinees and
controls.
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levels in vaccinated animals compared to controls. The emergence
of both KSA10-specific CTL and KSA10 escape mutant virus was
delayed in both vaccinated and control animals, and occurred
significantly after the establishment of a “set-point” viral load.
This suggests that this epitope may not be crucial to viral control
in these animals. The failure of vaccination to significantly accel-
erate the development of KSA10 responses may suggest that the
delayed response occurs as a result of late presentation of this
epitope, which is not accelerated by vaccination.
Compensatory mutations. Compensatory mutations outside
an epitope can partially restore the replicative capacity of viruses.
Certain patterns of linked mutations associated with CD8 T cell
epitope escape in highly conserved regions may also lead to vari-
able levels of viral fitness (13). The K165R Gag CTL escape muta-
tion has been shown to incur a significant fitness cost since the
mutation rapidly reverts toWT following in vivo passage inMHC-
mismatched animals (39, 48). This might suggest that, in the ab-
sence of compensatory mutations, the more rapid CTL escape
observed in the vaccinees would incur a fitness cost and lead to
reduced viremia. Since we did not in fact observe any virological
efficacy, we hypothesized that rapid development of compensa-
tory mutations may have evolved. We therefore examined the
pyrosequencing data outside the immunodominant epitopes for
evidence of mutations linked to the Gag K165R mutation.
We found that amutation 20 amino acids upstream of the KP9
epitope (V145A) that commonly followed the emergence of the
K165R mutation and was detected in 9 of 15 animals. This muta-
tion always emerged at a later time point relative to the KP9
(K165R) escapemutation. The V145Amutation could potentially
be either a newly identified escape mutation or a compensatory
mutation that occurs to overcome the substantial fitness cost of
the K165R mutation. The likelihood that the V145A mutation is
compensatory is strongly supported by (i) significant levels of the
V145A mutation above background sequencing errors (
0.9%)
only developed as the percentage of the K165R mutation ap-
proached 100% and not before and (ii) the fact that no CD4 or
CD8 T cell responses were detected across the V145A site from
peripheral blood mononuclear cell samples obtained from ani-
mals despite repeated efforts to detect them using peptide-stimu-
lated intracellular cytokine staining assays (data not shown).
FIG 5 Expression of 7high integrin on peripheral CD4 T cells. (A) Flow cytometry dot plot demonstrating transient loss of CD4CD957high T cells in blood
3 weeks after challenge with SIVmac251 in a representative vaccinated macaque. (B) Proportions of 7
high CD4 T cells of vaccinees (open symbols) and controls
(filled symbols) in blood before and after SIVmac251 challenge for individual macaques. Symbols for individual animals are as defined in Fig. 1. (C)Means (	 the
SE) of the proportions of 7high CD4 T cells in blood in vaccinees and controls.
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FIG 6 Evolution of KP9, KVA10 andKSA10 CTL escape. (A) Examples of K165RCTL escapemutation kinetics by using a strain-specific real-time PCR assay in serial
plasma RNA samples from controlmacaques (left panel) and vaccinees (right panel). (B toD) Examples of CTL escape by pyrosequencing in controls (left panels) and
vaccinees (right panels) for the threeCTLepitopesKP9 (B),KVA10 (C), andKSA10 (D).TheCTLaminoacid sequence is shown in thefirst column,with thepercentage
of the sequence in the subsequent columns and the timepoint after SIV challenge at the top of the column.Themutation identified is shown at each timepoint, with the
total reads shown in the bottom row. Common variants at each time point are shaded. Rarer variants account for the remaining sequences.
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The potential V145A compensatory mutation only occurred
relatively late in infection and the rate of selection of the V145A
mutation was relatively slow compared to the earlier K165R mu-
tations (Fig. 8A). Analysis of themaximum rate of development of
this putative compensatory mutation showed no significant dif-
ference between controls and vaccines (Fig. 8B). Of the animals in
which the V145A mutation was measured at 10% of total virus,
there was a slight trend for the V145A mutation to reach 10% of
total virus faster in vaccinated animals (76	 11 days versus 84	
9 days in controls, Fig. 8C), but this was not statistically signifi-
cant. This slower selection of a compensatorymutation compared
to the initial escape mutation might be expected, since the fitness
cost of escape is always lower than the “immune benefit” of escape
(39).Moreover, as previously shown, the fitness costs of mutation
are directly proportional to total CD4 T cell availability, so these
fitness costs may reduce over time in chronic infection (49). In
FIG 7 Rates of CTL escape in vaccinees and controls. (A) Example of CTL escape at KP9 in a vaccinee and a control determined using pyrosequencing. The time
taken to reach 50% EM (50:50 WT/EM, t50%) and maximal escape rates (bold lines, see Materials and Methods for the calculation) in a vaccinee and control
animal is shown. (B to D) 50% WT time (t50%, first panel) and escape rates (second panel) for all of the animals at the three epitopes—KP9, KVA10, and
KSA10—are shown. A Mann-Whitney test was used to determine whether differences between vaccinees and controls were statistically significant.
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addition, it seems likely that the V145Amutation may only partly
compensate for the fitness cost of K165R.
DISCUSSION
Developing a safe and effective HIV vaccine is a global health
priority. CD8 T cell immunity is clearly important in controlling
viremia in SIV-macaques (2, 5, 9, 50). Studying how CD8 T cells
induce effective immunity and determining the optimal set of
HIV-derived CD8 T cell antigens and utilization of these anti-
gens in appropriate vectors is a major goal of HIV vaccine design.
To understand the breadth of CD8 T cells required to facilitate
control of SIV viremia by vaccination, we inserted three immuno-
dominant SIV-specific CTL epitopes, Gag (KP9) and Tat (KSA10
and KVA10), into the influenza virus vector and analyzed the im-
munogenicity and protective efficacy of the vaccine. In addition,
the evolution of immune escape variants of recombinant influ-
enza viruses expressing the three SIV-specific CTL epitopes in
pigtail macaques was examined. Despite priming SIV-specific
CTL responses to these epitopes, there were no significant differ-
ences in the viral loads, loss of peripheral CD4 T cells or survival
between vaccinees and controls indicating that the vaccine did not
provide any protection from SIV disease progression. We were
unable to confirm that loss of 7high CD4 T cells in the periphery
was an indicator of disease progression as previously reported
(45). The physiological significance of 47 in SIV infection of
pigtail macaques is unclear and may be minimal.
The inability of the influenza virus vaccine with the three SIV
CTL epitopes to control viremia may illustrate the importance of
a broader base (
3 epitopes) of CD8 T cell responses in facilitat-
ing control of SIV (50, 51). Alternatively, the three SIV CD8 T cell
epitopes that we inserted into the influenza virus may not contain
the critical epitopes necessary to control SIV replication in pigtail
macaques. Recent studies have illustrated that a narrowly targeted
vaccine containing only 3 SIVCTL epitopes inducing SIV-specific
CD8 T cell responses was sufficient to control SIV replication in
Mamu-B*08 Indian rhesus macaques (7). Future studies in pig-
tail macaques testing a range of immunodominant epitopes may
assist in refining CTL-based control of primate lentiviruses. Fur-
thermore, CD4 T cell epitopes that generate functionally effec-
tive antibodies responses could be incorporated into vaccine vec-
tors to further probe the minimal base of immunity required for
protective efficacy.
The faster emergence of immune escape mutants at the Gag
KP9 and Tat KVA10 epitopes in the vaccinated macaques identi-
fied by both real-time PCR and pyrosequencing (Fig. 6 and 7)
suggests that the effectiveness of vaccine-induced CTL responses
can easily be undermined by rapid viral evolution (52). This may
be the consequence of only a small number of epitopes being
FIG 8 Rate of emergence of putative V145A compensatory mutation. (A) Rate of selection of the V145A and K165R mutation in a representative vaccinee and
controlmacaque asmeasured by the proportion of viruses containing the respectivemutations using pyrosequencing data. (B)MaximumV154Amutation rates
(per day) measured for controls and vaccinees determined using pyrosequencing data. (C) Time taken for the eight macaques (five controls, three vaccinees)
displaying the putative compensatory mutation V145A to reach 10% V145A, as assessed using pyrosequencing data.
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targeted or the selection of epitopes that do not effectively control
SIV viremia. Mudd et al. recently showed that vaccination with
gene fragments containing SIV epitopes more highly associated
with control of SIV viremia was more effective in controlling SIV
viremia, although this was undermined by immune escape in a
small subset of vaccinees (7). Recently, influenza virus A replicons
have been engineered that enable the expression of recombinant
proteins and green fluorescent protein (53, 54). If these vectors
could be engineered to express wholeHIV or SIV proteins or large
gene fragments, theymay be able to induce antibody or CD4 and
CD8 T cell responses.
We initially reasoned that faster CTL escapemight reduce virus
fitness and lead to some reduction in viremia; however, we did not
observe this. The extensive set of sequencing data from pyrose-
quencing from serial time points of viral RNA extracted from
plasma day 10 to week 20 enabled us to identify a putative com-
pensatorymutation (V145A) that was strongly associatedwith the
Gag KP9K165R escapemutation. Thismutationmaymitigate the
fitness cost associated with the primary CTL escape mutation.
Thus, the phenomenon of rapid viral escape and compensation
may pose a significant impediment to CTL-based vaccines target-
ing a small number of epitopes (50, 51).
There are several limitations to our studies. First, the CTL re-
sponses induced by the vaccines were modest and more potent
vaccines may reveal a greater impact on viral transmission, espe-
cially at the mucosae, as shown by Mudd et al. (7). We might also
expect, however, that a higher magnitude of CTL response di-
rected to a limited number or particular set of epitopes may drive
faster viral escape and compensation as previously demonstrated
when immunizing with a recombinant influenza virus construct
containing only one immunodominant Gag CTL epitope, KP9
(55). Second, although there were no significant differences in
viral loads between vaccinees and controls, we cannot exclude a
modest effect of vaccination. Even compensatory mutations may
not fully restore viral fitness. Third, although the putative V145A
compensatory mutation was strongly associated with the K165R
CTL escape mutation, detailed in vitro viral competition assays
with molecular clones will be required to confirm this.
HIV infections remain a major global health threat, and an
effective prophylactic vaccine is urgently needed. Our study dem-
onstrated that a vaccine based on three immunodominant CTL
epitopes in pigtail macaques was unable to protect animals from
high levels of viremia andCD4T cell loss after SIVmac251 challenge,
despite elicitation of modest SIV-specific responses postvaccina-
tion. Rapid evolution of both CTL responses and compensatory
mutations are likely to be the major causes of the failure of this
vaccine. We conclude that CTL based vaccines need to induce
stronger immune responses to specific CTL epitopes that are per-
tinent to the protection of pigtail macaques from SIV.
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